CAS: 4313-03-5; (2E,4E)-Hepta-2,4-Dienal

相似化合物

1576-87-0 30361-28-5 33467-79-7

上下游产品

(2E,4E)-hepta-2,4-dienoic acid propionaldehyde trans-Crotonaldehyde cyclopropylmagnesium bromide(2E,4E)-hepta-2,4-dienoic acid t-dien-t-yl-1,3-diphenyl-imidazolidine2-hexa-1,3t-dien-t-yl-1,3-diphenyl-imidazolidine E,E,E,E-2,4,6,8-Undecatetraenal (E,E,E)-2,4,6-nonatrienal

(2E,4Z)-Hepta-2,4-Dienoic Acid Methyl Ester置于manganese(Iv) Oxide,Lithium Aluminium Tetrahydride体系中,用 乙醇,Petroleum Ether 作为反应溶剂,化学反应 2.5H,反应生成 (E,E)-2,4-庚二烯醛
参考文献:Highly Stereocontrolled Synthesis Of (2E,4Z)-Dienic Esters By Alumina Catalyst
标题:Highly Stereocontrolled Synthesis Of (2E,4Z)-Dienic Esters By Alumina Catalyst
摘要:
DOI:10.1016/s0040-4039(00)86787-8

专利信息

专利号:US-2005004225-A1
优先权日:2003-04-16
标题:Oxidoreductase inhibitors and methods of screening and using thereof
发明人：BALENDIRAN GANESARATNAM K
摘要:The present invention relates to 1) the design and synthesis of analogs to glutathione conjugates which bind to or interact with aldose reductase (AR) through unique conformations that are distinctly different from the substrates and inhibitors of AR which are members of sugar metabolism; 2) the screening of the analogs to identify those that interact with or inhibit or enhance the activity of AR; and 3) the use of AR ligands, AR inhibitors (AR antagonsits) or AR enhancer (AR agonists) in the detection of AR activity, the modulation of AR activity, and the treatment of conditions in a subject in need of modulating AR activity. Such conditions include but not limited to cardiovascular disease, diabetes, artheriosclerosis, cancer, neoplasm, obesity, cataract, retinopathy, keratopathy, nephropathy, neurosis, thrombosis, faulty union of corneal injury and neuropathy. Examples of the treatment include the use of fibrates as AR inhibitors to treat these conditions.

专利号:US-7329767-B2
优先权日:2003-10-03
标 题:Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof
发明人：DEWIS MARK L; JOHN THUMPLASSERIL V; ECKERT MARKUS A; COLSTEE JAN HERMAN; DA COSTA NEIL C; PEI TAO
权利人:INT FLAVORS & FRAGRANCES INC
摘要:Described are mixtures of at least four of the alkadienamides defined according to the structure: n nwherein R represents C 1 -C 2 n-alkyl; R 1 is 2-methyl-1-propyl and R 2 is hydrogen, or R 1 and R 2 taken together is a moiety having the formulan n nwherein n is 4 or 5, or compositions containing substantial concentrations of such mixtures, prepared according to novel processes: (a) extraction of a ground substantially dried fruit of one of the Piper species, Piper longum Linn or Piper peepuloides ; (b) natural product-forming synthesis; or (c) synthetic product-forming synthesis. Also described are uses of the thus-formed products for augmenting, enhancing or imparting an aroma, taste, chemesthetic effect and/or antibacterial effect in or to a consumable material and/or in the oral cavity and/or on the mammalian epidermis.

专利号:US-8007841-B2
优先权日:2003-10-03
标 题 :Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof
发明人：JOHN THUMPLASSERIL V; ECKERT MARKUS A; DEWIS MARK L; COLSTEE JAN HERMAN; DA COSTA NEIL C
权利人:INT FLAVORS & FRAGRANCES INC
摘要:Described are mixtures of at least four of the alkadienamides defined according to the structure: n nwherein R represents C 1 -C 2 n-alkyl; R 1 is 2-methyl-1-propyl and R 2 is hydrogen, or R 1 and R 2 taken together is a moiety having the formula —(CH 2 ) n —, wherein n is 4 or 5, or compositions containing substantial concentrations of such mixtures, prepared according to novel processes: (a) extraction of a ground substantially dried fruit of one of the Piper species, Piper longum Linn or Piper peepuloides ; (b) natural product-forming synthesis; or (c) synthetic product-forming synthesis. Also described are uses of the thus-formed products for augmenting, enhancing or imparting an aroma, taste, chemesthetic effect and/or antibacterial effect in or to a consumable material and/or in the oral cavity and/or on the mammalian epidermis.

专利号:US-2005282781-A1
优先权日:2004-06-18
标 题 :Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
发明人：GHOSAL SHIBNATH
权利人:GHOSAL SHIBNATH
摘要:An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested/shown that C 20:5n-3 (and C 22:6 n-3 ) PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA,—the precursors of DBPs.

专利号:US-7671085-B2
优先权日:2002-11-15
标 题 :Non-steroidal farnesoid X receptor modulators and methods for the use thereof
发明人：DOWNES MICHAEL R; EVANS RONALD M
权利人:SALK INST FOR BIOLOGICAL STUDI
摘要:The efficient regulation of cholesterol synthesis, metabolism, acquisition, and transport is an essential component of lipid homeostasis. The farnesoid X receptor (FXR) is a transcriptional sensor for bile acids, the primary product of cholesterol metabolism. Accordingly, the development of potent, selective, small molecule agonists, partial agonists, and antagonists of FXR would be an important step in further deconvoluting FXR physiology. In accordance with the present invention, the identification of novel potent FXR activators is described. Two derivatives of invention compounds, bearing stilbene or biaryl moieties, contain members that are the most potent FXR agonists reported to date in cell-based assays. These compounds are useful as chemical tools to further define the physiological role of FXR as well as therapeutic leads for the treatment of diseases linked to cholesterol, bile acids and their metabolism and homeostasis.

专利号:US-5708168-A
优先权日:1994-11-16
标 题 :Azepine compounds
发明人：KEANA JOHN F W; GUZIKOWSKI ANTHONY P; NOGALES DANIEL F; CAI SUI XIONG
权利人:OREGON STATE; ACEA PHARM INC
摘要:Disclosed are methods of preparing azepines by a multistep synthesis including a Diels-Alder reaction. Also disclosed are methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment an azepine which has high binding to the NMDA glycine site.